TARGET AUDIENCE
This activity has been designed to meet the educational needs of medical oncologists and other allied healthcare professionals involved in the treatment of prostate cancer, urothelial bladder cancer and renal cell carcinoma (RCC).

OVERVIEW OF ACTIVITY
The past several years have seen an explosion in the emergence of new potential therapies that leverage the natural ability of the human body to attack and treat cancer. Known as immune-mediated therapies, or cancer immunotherapies, these promising treatments are taking center stage at medical conferences and generating excitement all over the world. Not surprisingly, with the many exciting advances rapidly occurring both within the field of genitourinary (GU) tumors and elsewhere, a number of vexing questions and clinical challenges are emerging simultaneously.

These proceedings from a CME symposium during the Genitourinary Cancers Symposium explore the most significant therapeutic advances in the field of immunotherapy by using the perspectives of leading GU cancer experts on challenging cases and questions submitted by clinicians in the community to frame a relevant discussion of how this information has aided in the refinement of current routine clinical practice and ongoing research. This CME activity will help medical oncologists and other allied healthcare professionals find answers to the individualized questions and concerns that they frequently encounter and in turn provide high-quality cancer care.

LEARNING OBJECTIVES

• Compare and contrast the mechanisms of action, efficacy and safety/toxicity of approved and investigational immunotherapies for the treatment of prostate cancer, RCC and bladder cancer to determine the current and/or potential utility of these agents in clinical practice.
• Appraise the rationale for and clinical data with approved anti-PD-1 and anti-PD-L1 antibodies in patients with metastatic RCC and bladder cancer, and use this information to select patients for treatment with an immune checkpoint inhibitor.
• Describe ongoing research to assist in the identification of biomarkers, tumor characteristics or other clinical features that are indicative of response to immune checkpoint inhibitors in patients with GU cancers.
• Evaluate typical and atypical patterns of response to immune checkpoint inhibitors in an effort to identify patients who may or may not be benefiting from these agents.
• Recognize immune-related adverse events and other common side effects associated with approved and developmental immune checkpoint inhibitors, and use this information to develop supportive management plans for patients with GU cancers undergoing treatment with these agents.
• Consider available and emerging data with investigational anti-PD-1/PD-L1 antibodies alone or in combination with other systemic approaches currently in Phase II/III testing for select GU cancers, and, where applicable, refer eligible patients for trial participation or expanded access programs.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Charles G Drake, MD, PhD
Professor of Medicine
Co-Director, Cancer Immunotherapy Programs
Columbia University Medical Center
New York, New York

Consulting Agreements: Agenus Inc, Dendreon Pharmaceuticals Inc, Genentech BioOncology, ImmuneXcite, Janssen Biotech Inc, Lilly, Merck, NexImmune, Pierre Fabre, Roche Laboratories Inc; Contracted Research: Aduro Biotech, Bristol-Myers Squibb Company, Janssen Biotech Inc; Patents: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Janssen Biotech Inc; Stockholder: Compugen, NexImmune, Potenza Therapeutics, Tizona Therapeutics Inc; Other: Bristol-Myers Squibb Company.

Peter H O’Donnell, MD
Assistant Professor, Department of Medicine
Section of Hematology/Oncology
Genitourinary Oncology Program
The University of Chicago
Chicago, Illinois

Contracted Research: Acerta Pharma, AstraZeneca Pharmaceuticals LP/MedImmune, Boehringer Ingelheim Pharmaceuticals Inc, Genentech, A Member of the Roche Group, Janssen Biotech Inc, Merck, Seattle Genetics; Expert Testimony: Temple Health, Trinity Health; Honoraria: Algeta ASA, American Medical Forum, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Genentech, A Member of the Roche Group, Harrison Consulting, Inovio Pharmaceuticals Inc, Janssen Biotech Inc, Kantar Health, Merck, Novartis, PAREXEL International Corporation, Quintiles, Seattle Genetics, Xcenda; Stock: Allergan Inc; Travel: Merck.

Elizabeth R Plimack, MD, MS
Director, Genitourinary Clinical Research
Associate Professor, Department of Hematology/Oncology
Fox Chase Cancer Center, Temple Health
Philadelphia, Pennsylvania

Advisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Exelixis Inc, Genentech BioOncology, Horizon Pharma, Inovio Pharmaceuticals Inc, Lilly, Novartis, Pfizer Inc, Roche Laboratories Inc; Contracted Research: Acceleron Pharma, Agensys Inc, a subsidiary of Astellas Pharma US, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Merck, Peloton Therapeutics Inc, Pfizer Inc.

Thomas Powles, MBBS, MRCP, MD
Professor of Urology Oncology
Director of St Bartholomew’s Cancer Centre
Queen Mary University of London
London, United Kingdom

Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Roche Laboratories Inc.

David I Quinn, MBBS, PhD
Medical Director, Norris Cancer Hospital and Clinics
Head, GU Cancer Section
Division of Cancer Medicine and Blood Diseases
USC Norris Comprehensive Cancer Center
Los Angeles, California

Advisory Committee: Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals Inc, Exelixis Inc, Genentech BioOncology, Janssen Biotech Inc, Merck, Pfizer Inc, Sanofi Genzyme; Consulting Agreements: Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Dendreon Pharmaceuticals Inc, Exelixis Inc, Genentech BioOncology, Janssen Biotech Inc, Merck, Pfizer Inc, Sanofi Genzyme.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Genentech BioOncology and Merck.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Release date: April 2018
Expiration date: April 2019